Asunto(s)
Carcinoma Basocelular , Microscopía Confocal , Pezones , Neoplasias Cutáneas , Tomografía de Coherencia Óptica , Humanos , Carcinoma Basocelular/patología , Carcinoma Basocelular/diagnóstico por imagen , Pezones/patología , Pezones/diagnóstico por imagen , Tomografía de Coherencia Óptica/métodos , Neoplasias Cutáneas/patología , Neoplasias Cutáneas/diagnóstico por imagen , Microscopía Confocal/métodos , Femenino , Neoplasias de la Mama/patología , Neoplasias de la Mama/diagnóstico por imagen , Anciano , Persona de Mediana EdadRESUMEN
Background and Objectives: JAK inhibitors entered current clinical practice as treatment for several immune-related diseases and, recently, for atopic dermatitis. These drugs target the Janus Kinase intracellular cascade, rendering them suitable for treating both Th1 and Th2 immune-mediated responses. Materials and Methods: We report the case of a 36-year-old male patient presenting an overlap of ulcerative colitis, a Th1-related disease, and atopic dermatitis, a Th2-mediated condition. Treatment with upadacitinib was initiated, and laboratory and instrumental follow-ups were carried out for 8 months. Results: The complete and persistent clinical remission of both conditions was observed at a low dose of 15 mg of upadacitinib, even though ulcerative colitis guidelines usually recommend a dosage of 45 mg. No serious adverse responses to therapy were reported. Conclusions: Upadacitinib may be the most suitable management strategy in subjects with coexisting severe conditions mediated by Th1 inflammation, such as ulcerative colitis, and by Th2 cytokines, such as atopic dermatitis.